Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2005

View Archived Issues

New mode of cell death achieved with novel CDK4 homologous peptide

Targeting urotensin II for CHF and restenosis following balloon angioplasty

Apoptosis-inducing metal-based complexes described by Irish scientists

Allergy Therapeutics updates status of allergy vaccine programs

Senexis and Galapagos expand collaboration

Idenix outlines plans for valopicitabine phase III trials

Positive results disclosed from MEND-CABG study of MC-1

FDA gives feedback on phase III study protocol for cethromycin in CAP

Cel-Sci signs cooperative agreement with NIAID to test CEL-1000 for bird flu

Study to investigate Phytosel's ability to lower chemotherapy side effects

UGT1A1 test launched to determine appropriate Camptosar dosage

VX-950 enters phase II development for HCV

Neuren raises funding to advance neurological compounds

Merck submits Gardasil BLA

Hylenex receives FDA approval

PXD-101: update on cancer studies

Phenoxodiol effective for malignant SCC of the cervix, vagina or vulva and advanced prostate cancer

Targeting Tie-1 for cancer

A benzodiazepine modulates c-myc

Targeting tissue factor enhances paclitaxel activity

Data on human monoclonal antibodies to TRAIL receptors

Preclinical studies show curcumin prevents breast cancer metastasis

New therapeutics for cancer disclosed in recent patents

Novel agents for alopecia, psoriasis claimed in recent patents

DailyDrugNews.com invites users to participate in Reader Survey

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...